O. M. Kudelina, E. Gantsgorn, Yu. S. Maklyakov, D. L. Tkachenko, L. A. Avakyan, P. A. Chubyreva, Y. G. Amirova, Yu. A. Karpova, A. N. Dulskaya, I. B. Meshi
{"title":"Clinical Course and Therapy Methods of Aquagenic Urticaria","authors":"O. M. Kudelina, E. Gantsgorn, Yu. S. Maklyakov, D. L. Tkachenko, L. A. Avakyan, P. A. Chubyreva, Y. G. Amirova, Yu. A. Karpova, A. N. Dulskaya, I. B. Meshi","doi":"10.33647/2713-0428-19-3e-130-135","DOIUrl":null,"url":null,"abstract":"Aquagenic urticaria is one of the rarest forms of allergic reaction in the body. Aquagenic urticaria is clinically manifested by itching and urticarial rashes 5–10 min after contact with water. The signs disappear within 30–60 min. The standard therapy regimen includes the administration of second-generation H1-histamine receptor blockers and barrier creams with ceramides. In recent years, the use of monoclonal antibody therapy (omalizumab) has been considered in cases where antihistamines are ineffective.","PeriodicalId":14837,"journal":{"name":"Journal Biomed","volume":"68 7","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal Biomed","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33647/2713-0428-19-3e-130-135","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Aquagenic urticaria is one of the rarest forms of allergic reaction in the body. Aquagenic urticaria is clinically manifested by itching and urticarial rashes 5–10 min after contact with water. The signs disappear within 30–60 min. The standard therapy regimen includes the administration of second-generation H1-histamine receptor blockers and barrier creams with ceramides. In recent years, the use of monoclonal antibody therapy (omalizumab) has been considered in cases where antihistamines are ineffective.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
